Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astria Therapeutics (ATXS) EBITDA: 2017-2018

Historic EBITDA for Astria Therapeutics (ATXS) over the last 2 years, with Dec 2018 value amounting to -$6.1 million.

  • Astria Therapeutics' EBITDA fell 10.75% to -$6.1 million in Q4 2018 from the same period last year, while for Dec 2018 it was -$26.4 million, marking a year-over-year increase of 2.79%. This contributed to the annual value of -$26.4 million for FY2018, which is 2.67% up from last year.
  • Per Astria Therapeutics' latest filing, its EBITDA stood at -$6.1 million for Q4 2018, which was down 1.33% from -$6.0 million recorded in Q3 2018.
  • Astria Therapeutics' EBITDA's 5-year high stood at -$5.5 million during Q4 2017, with a 5-year trough of -$7.8 million in Q1 2017.
  • Over the past 2 years, Astria Therapeutics' median EBITDA value was -$6.8 million (recorded in 2017), while the average stood at -$6.7 million.
  • Data for Astria Therapeutics' EBITDA shows a peak YoY increase of 13.58% (in 2018) and a maximum YoY decrease of 10.75% (in 2018) over the last 5 years.
  • Over the past 2 years, Astria Therapeutics' EBITDA (Quarterly) stood at -$5.5 million in 2017, then declined by 10.75% to -$6.1 million in 2018.
  • Its EBITDA stands at -$6.1 million for Q4 2018, versus -$6.0 million for Q3 2018 and -$6.6 million for Q2 2018.